MedTrace Logo

An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM

NCT04004078 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 314

Last updated 2022-04-20

No results posted yet for this study

Summary

This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University from March 2018 to April 2020.

Conditions

  • Invasive Fungal Infection

Interventions

DEVICE

other antifungal agents,breathing machine

If treatment failure for patients in group A，group B，group C and group D，change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Sponsors & Collaborators

  • People's Hospital of Zhengzhou University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2021-04-30
Completion
2021-05-01
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004078 on ClinicalTrials.gov